Vancouver, British Columbia–(Newsfile Corp. – February 8, 2023) – EGF Theramed Health Corp. (CSE: TMED) (OTC Pink: EVAHF) (FSE: AUH) (the “Company” of “EGF“) is pleased to announce it has progressed forward and is now very close to acquiring various dispensary targets in British Columbia. Having looked at targets throughout Canada for the last few months, the market has become increasingly favorable to acquire assets from distressed single store operators favoring scaled centralized operations. Many single store operators that gained an early mover advantage have felt the effects COVID to their bottom line giving EGF an advantage in its acquisitions.

“Since joining Theramed it has been my goal to hand pick the highest quality assets with optimal value. Our company has the ability to raise capital quickly and therefore make significant acquisitions that will lead to instant significant revenue. Our first targeted acquisition is on Vancouver Island, which is famous for its cannabis production and we feel is significantly undervalued. In the coming period, we will look to take this company into generating multimillion revenue; pending we are able to find high value acquisition targets,” states Connor Yuen, CEO.

EGF Theramed has been looking for specific dispensaries that are specially designed to convert and attract customers into the local legal cannabis market. Through the acquisition of established retail outlets, the Company will develop a retail experience that fosters a community and builds a network of customers. The Company expects to offer a large selection of cannabis products and to offer educational materials and resources to customers. The company is targeting prime real estate in high foot traffic areas to maximize consumer accessibility. “We see a huge advantage to expanding our business operations into the retail space. Creating a direct line of communication with the end consumer and obtaining further insight into consumer habits directly aligns with our goals in addition to elevating our revenues. This will be the first step of many in incorporating technology and innovation with the Company’s long-term vision,” states Connor Yuen, Chief Executive Officer, EGF Theramed Health.

With the increase in cannabis consumption, EGF aims to capitalize on the retail market opportunity, creating another favourable section of the business. Around 50% of cannabis users reported increased consumption since the start of the pandemic. Generation Z’s market share has doubled over the course of the last two years (from 8.3% in the first quarter of 2020 to 15% in the last quarter of 2021), making them the demographic with the highest rise.¹ The size of the legal adult-use cannabis market in Canada stands at $5.43 billion Canadian Dollars in 2022. By 2026, this market is forecast to reach $10.44 billion Canadian Dollars.² The market data shows the growth trajectories increasing at an accelerated pace, giving EGF substantial room for growth with its potential retail assets.

The Company continues to seek potential partnerships and acquisitions in addition to the current opportunity under review. Further, the Company expects to engage online marketing for a sum of $250,000 USD to broaden the Company’s reach within the investment community, increasing investor awareness of the Company, and attracting potential new investors through various on-line platforms and methods of engagement. The marketing services include project management and consulting for an on-line marketing campaign, coordinating marketing actions, maintaining and optimizing AdWords campaigns, adapting AdWords bidding strategies, optimizing AdWords ads, and creating and optimizing landing pages. The promotional activity will occur by e-mail, Facebook and Google.

ABOUT EGF THERAMED HEALTH CORP.

(CSE: TMED) (OTC Pink: EVAHF) (FSE: AUHP)

EGF is a consumer technology company engaged in the provision of biomedical online services for monitoring and treating common health problems. The Company, through its subsidiaries, has assets and technologies used in the extraction and purification of botanical extracts and the creation of extract formulations, as well as medical monitoring device technology. The Company is working to collaborate with other companies for medical technology, equipment protocols and laboratory SOPs.

For more information please contact:

EGF THERAMED HEALTH CORP.

Doug McFaul
Email: [email protected]
Telephone: (778) 331 8505
Website: http://www.theramedhealthcorp.com
CSE Micro-site: http://thecse.com/en/listings/technology/Theramed-Health-Corporation
US OTC Markets (OTCQB): http://www.otcmarkets.com/stock/EVAHF/news
Frankfurt Borse: http://www.boerse-frankfurt.de/equity/egf-theramed-health-corp-1

CAUTIONARY LANGUAGE

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to the completion of the Transaction contemplated by the Term Sheet. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

¹ https://www.npws.net/blog/cannabis-industry-statistics
² https://www.statista.com/statistics/1244942/canada-legal-recreational-cannabis-market-size/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

DENVER , March 4, 2022 /PRNewswire/ — Item 9 Labs Corp. (OTCQX: INLB) (the “Company”) — a vertically integrated cannabis dispensary franchisor and operator that produces premium, award-winning products — announced today that it has closed its acquisition of an existing dispensary license and storefront in Adams County, Colorado.

Located at 6101 N. Washington St. in Denver, this will be the first corporate-owned shop under the Unity Rd. brand. The Company expects the shop to be operational in the first half of 2022.

Acquisition Marks First in Company’s National Growth Accelerator

This acquisition is part of an overarching strategy to accelerate national development by creating turnkey investment opportunities for Unity Rd. franchise partners. Item 9 Labs Corp. plans to aggressively expand its dispensary franchise by acquiring and converting cannabis retail stores, training the local team and selling the business to new and existing franchise partners.

“Entrepreneurs are flocking to cannabis, eager to grab a piece of the $25 billion a year market, but soon find that opening a cannabis business is most often a lengthy, complex process,” said Item 9 Labs Corp.’s Chief Executive Officer, Andrew Bowden. “This development strategy offers one of the most turn-key entrances into cannabis. With our team handling the acquisition, conversion and training internally, we expect our national Unity Rd. footprint to expand much more quickly.”

As part of these development efforts, the Company is seeking acquisitions of cannabis dispensaries in Denver, front range and compelling mountain towns throughout Colorado, and key markets in Arizona, Michiganand Oklahoma.

“Unity Rd. is the growth vehicle that will bring our award-winning, premium Item 9 Labsproducts to new states,” added the Company’s Chief Strategy Officer, Jeffrey Rassas. “We are also seeking opportunities to acquire, develop or partner with cultivation and production facilities in markets where we have two to three Unity Rd. shops to ease new market product entry and focus our operations.”

Bringing Item 9 Labs products to markets where Unity Rd. shops are located gives franchise partners front-of-the-line access to a reliable, award-winning product supply chain. The cannabis retail shop also benefits from the national product consistency that consumers have come to expect from franchise brands.

More Information on Item 9 Labs Corp. and Unity Rd.:
Visit https://investors.item9labscorp.com/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

National Cannabis Dispensary Franchise Progresses Midwest Growth; Local Alliance Program Aims to Keep Dispensary Ownership Local by Providing Existing Owners the Backing of a National Franchise System

OKLAHOMA CITY, Jan. 27, 2022 /PRNewswire/ — Unity Rd., the cannabis dispensary franchise from Item 9 Labs Corp. (OTCQX: INLB), announced today it has signed its first partner through its Local Alliance Program with an Oklahoma City dispensary, Ringside Medical. The shop is located at 14201 N. May Ave. #205 and will be rebranded to Unity Rd.

Unity Rd. launched the Local Alliance Program in 2021 to support local dispensary ownership. Through the program, existing cannabis dispensary owners and license holders can partner with Unity Rd. to gain direct access to the buying power, resources and supportive network normally reserved for multi-unit operators. Partners through this program retain 100% ownership of their dispensary license and business and benefit from the tools, expertise and ongoing support necessary to compliantly and successfully operate a dispensary.

“The U.S. cannabis landscape is comprised of small, independent entrepreneurs and giant, multi-state operators,” said Unity Rd.’s Chief Franchise Officer Mike Weinberger. “With the added layer of complexities that cannabis brings by being federally illegal and so highly regulated, it is challenging for independents to compete with conglomerates that have teams of industry experts who are dedicated to compliance, accounting, marketing, etc. and know how to navigate the intricacies of cannabis.”

Weinberger continued, “The franchise model gives prospective and existing dispensary owners a fighting chance by empowering them with the knowledge, relationships and ongoing support they need to be compliant and focused on growing their business, rather than stuck in day-to-day management.”

“Having the supportive network of a franchise will be a tremendous weight off us and our team,” said Ringside Medical Co-Owner Robin O’Grady. “Cannabis is complicated. You need to constantly be on your toes and able to pivot at a moment’s notice. By joining Unity Rd., we’re expanding our team with experts who have operated cannabis businesses in multiple states and gaining several other benefits that will positively impact our future growth.”

The Local Alliance shop is primed for growth as Oklahoma’s medical cannabis market has surpassed $1.5 billion in revenue since legal sales began in 2018. The state has one of the largest medicinal programs in the U.S. with about 10% of the population, nearly four million residents, having obtained a medical card. Further, Oklahoma activists have already filed two ballot measures this year to legalize adult-use cannabis and overhaul the state’s medical cannabis system.

“We’re hopeful this Local Alliance shop will be the first of many Unity Rd. shops across Oklahoma,” said the marijuana franchise’s Vice President of Franchise Development Justin Livingston. “We’re confident that our team can help owners increase their dispensary’s value within their local communities.”

In addition to Oklahoma, the cannabis franchise is actively seeking partnerships with existing dispensary owners across the United States who would benefit from the systems, processes and ongoing support the franchise offers. Unity Rd. also partners with industry newcomers and currently has multiple agreements signed with nearly 20 entrepreneurial groups who are in various stages of development nationwide. The franchise offers one of the safest routes for cannabis entrepreneurs looking to stake their claim in the fast-growing, complex industry. Backed by time-tested Standard Operating Procedures (SOPs) and an accomplished team boasting more than 200 years of combined experience in cannabis and franchising, franchise partners are guided through every operational function of the business – whether it be assisting with cash flow, product selection or changing regulations.

To learn more about the Unity Rd. Local Alliance Program, contact [email protected] or call 480-542-9420.

For more information about the Unity Rd. Franchise Opportunity, contact [email protected], call 720-923-5262 or visit unityrd.com.

About Unity Rd.
Unity Rd. is bridging the two previously disconnected worlds of cannabis and franchising. The industry trailblazer is the first to bring the cannabis dispensary franchise model to the United States—with duality of prowess in both industries to back it up. Built up from a collective 200 years in the legal cannabis industry and franchising, the company helps eager operators enter the complex industry with ease. The marijuana franchise pioneer offers its partners the knowledge, resources, and ongoing support needed to compliantly and successfully operate a dispensary. Launched in 2018, Unity Rd. has signed multiple agreements with nearly 20 entrepreneurial groups across the country. Recently, it was named one of the top cannabis retail leaders in the nation by MJBizDaily magazine and one of the “Best Cannabis Companies to Work For” in both the dispensary and cultivation categories in Cannabis Business Times’ elite 2020 list. The company is also the first cannabis business to earn a Franchise Times Dealmakers award. For more information, visit unityrd.com.

About Item 9 Labs Corp.
Item 9 Labs Corp. (OTCQX: INLB) is a vertically integrated cannabis operator and dispensary franchisor delivering premium products from its large-scale cultivation and production facilities in the United States. The award-winning Item 9 Labs brand specializes in best-in-class products and user experience across several cannabis categories. The company also offers a unique dispensary franchise model through the national Unity Rd. retail brand. Easing barriers to entry, the franchise provides an opportunity for both new and existing dispensary owners to leverage the knowledge, resources, and ongoing support needed to thrive in their state compliantly and successfully. Item 9 Labs brings the best industry practices to markets nationwide through distinctive retail experience, cultivation capabilities, and product innovation. The veteran management team combines a diverse skill set with deep experience in the cannabis sector, franchising, and the capital markets to lead a new generation of public cannabis companies that provide transparency, consistency, and well-being. Headquartered in Arizona, the company is currently expanding its operations space by 650,000+ square feet on its 50-acre site, one of the largest properties in Arizona zoned to grow and cultivate flower. For additional information, visit item9labscorp.com.

Media Contact:
Marisa Beaumont
Fishman PR
[email protected]
847-945-1300

Investor Contact:
Item 9 Labs Corp.
[email protected]
800-403-1140

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Names Eric C. Kutscher and Lawrence X. Taylor to Board of Directors; Adds a Combined 55-Plus Years of Experience Across Patient-Centered Healthcare, Leadership, M&A and Strategic Planning

PHOENIX, Jan. 4, 2022 /PRNewswire/ — Item 9 Labs Corp. (OTCQX: INLB) (the “Company”)—a vertically integrated cannabis dispensary franchisor and operator that produces premium, award-winning products—announced today that Eric C. Kutscher, Pharm. D., M.B.A., F.A.S.H.P., and Lawrence X. Taylor have been appointed to its Board of Directors.

“Eric and Lawrence have vastly different backgrounds that will enrich our foundation across several core growth areas of the company,” says Andrew Bowden, CEO of Item 9 Labs Corp.

Currently, the Company’s cannabis dispensary franchise brand, Unity Rd., has a franchisee-owned shop operating in Boulder, Colorado, as well as a corporate-owned shop opening soon in Adams County, Colorado, and agreements signed with nearly 20 partners who are in various stages of opening their Unity Rd. shops across Maine, Michigan, New Jersey, and Virginia, among other states. Item 9 Labs is the most in demand brand at more than 54% of Arizona’s dispensaries, according to LeafLink, and has earned more than 20 podium finishes in Arizona marijuana competitions. The Company is near completing development of its cultivation site in Nevada, recently started phase one of its master cultivation site development in Arizona and is seeking dispensary acquisitions to accelerate national growth.

Bowden added, “As we look ahead to expanding our products and franchise brands nationally, their depths of expertise will be a tremendous value.”

Kutscher and Taylor’s appointments demonstrate the Company’s focus on strengthening its corporate governance through more independent directors.

About Eric C. Kutscher:

Kutscher has 25-plus years of experience leading high-performing teams and is a thought leader in the delivery of patient-centered healthcare, research, academia, and leadership. He started his career in academic psychiatry and pharmacology and progressed to full clinical professor positions at three universities.

In 2013, Kutscher retired from his academic role to pursue healthcare executive opportunities and consulting. He has consulted with well-known companies such as SpotRx/MedAvail, MeMD, UAMC, UArizona/SinfroniaRx, TribalEM/Tribal Health, San Carlos Apache Healthcare, Pill Nurse, Walgreens, Connections Health Solutions, and various legal firms. Kutscher is currently the Senior Director for Clinical Operations and Pharmacy Services for Arizona Oncology Associates, the largest privately held Oncology practice in the state of Arizona, where he was hired to provide change leadership.

“What attracted me to Item 9 Labs Corp. was their vision and focus to bring credibility to the industry with very high-quality products as well as service to help people understand cannabis and all the potential therapeutic benefits beyond just a recreational high,” said Kutscher, noting that Unity Rd. appeals to consumers in both new and mature markets, leading with an education-first approach to guide individuals to the right products. “We have an opportunity to create industry standards and help people feel comfortable exploring cannabis as medicine.”

About Lawrence X. Taylor:

Taylor brings a diverse perspective to the boardroom, combining deep financial expertise, strategy, and governance to deliver thoughtful questions and insights that help drive informed decisions. As a C-level executive, advisor, and board member with more than 30 years of business experience, he has guided organizations through complex restructurings, acquisitions, corporate development activities and capital transactions totaling more than $15 billion. He possesses an extensive knowledge of finance, strategy and operations and has developed strategic, financial, operating and turnaround strategies across multiple industries including casino gaming, hospitality, manufacturing, aviation, real estate, and retail operations.

Lawrence currently serves on the boards of Barrie House Coffee and CLP Holdings III, LLC. At Barrie House Coffee, he chairs the M&A committee and serves on the Strategic Planning Committee. Previously, he served on the boards and committees (M&A, Strategic Planning, Restructuring, Finance and Compensation) of multiple companies. He has also served as a Board Member and Treasurer on the Finance and Compensation Committees for Sojourner Center and as a Board Member and Treasurer for E Tabs Manufacturing.

“Item 9 Labs Corp. is transforming the cannabis industry by utilizing the franchise model to drive retail growth and bring their products to new markets,” Taylor said. “It’s been exciting to watch their development and I’m honored to work with their leadership team to help bolster continued success.”

For more information on Item 9 Labs Corp. and its brands, visit https://investors.item9labscorp.com/.

About Item 9 Labs Corp.
Item 9 Labs Corp. (OTCQX: INLB) is a vertically integrated cannabis operator and dispensary franchisor delivering premium products from its large-scale cultivation and production facilities in the United States. The award-winning Item 9 Labs brand specializes in best-in-class products and user experience across several cannabis categories. The company also offers a unique dispensary franchise model through the national Unity Rd. retail brand. Easing barriers to entry, the franchise provides an opportunity for both new and existing dispensary owners to leverage the knowledge, resources, and ongoing support needed to thrive in their state compliantly and successfully. Item 9 Labs brings the best industry practices to markets nationwide through distinctive retail experience, cultivation capabilities, and product innovation. The veteran management team combines a diverse skill set with deep experience in the cannabis sector, franchising, and the capital markets to lead a new generation of public cannabis companies that provide transparency, consistency, and well-being. Headquartered in Arizona, the company is currently expanding its operations space up to 640,000+ square feet on its 50-acre site, one of the largest properties in Arizona zoned to grow and cultivate flower. For additional information, visit item9labscorp.com.

Media Contact:
Item 9 Labs
Jayne Levy, VP of Communications
[email protected]

Investor Contact:
Item 9 Labs Corp.
[email protected]
800-403-1140

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Las Vegas, Nevada–(Newsfile Corp. – November 23, 2021) – Bhang Inc. (CSE: BHNG) (OTCQB: BHNGF) (“Bhang” or the “Company“), a global cannabis CPG brand company with an award-winning portfolio of products, is officially available in Florida through its licensing partner, Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) and its subsidiaries (“Trulieve“).

In September, Bhang and Trulieve announced an expanded licensing agreement to manufacture and distribute Bhang’s award-winning, THC-infused chocolate products across all Trulieve markets, both in Trulieve dispensaries and through the company’s robust sales and distribution networks. Bhang products were introduced through Massachusetts retail and wholesale in October 2021, and are now available in Florida exclusively through Trulieve dispensaries. Trulieve is Florida’s largest and leading medical cannabis provider with 108 dispensaries across the state.

Bhang is known for its gourmet chocolate, a top-ten selling product in both the U.S. and Canada with evenly-scored bars for precise THC dosing. Bhang products available through Trulieve in Florida include:

• THC:CBD 1:1 Dark Chocolate Bars – Bhang’s signature, cannabis-infused, vegan dark chocolate is made with 74% sustainably sourced cacao and a cannabis-free taste. The dark bar is vegan, keto and gluten-free.
• THC:CBD 1:1 Milk Chocolate Bars – Bhang’s cannabis-infused milk chocolate is made with 48% sustainably sourced cacao, a cannabis-free taste and is vegetarian and gluten-free.

“Since launching in Massachusetts in October, Bhang sales and orders through Trulieve have far exceeded our expectations, and we are excited to keep the momentum going in Florida, where we know the demand for our products is already high,” says Jamie L. Pearson, President and CEO of Bhang. “We are currently working on rolling out new SKUs with the Trulieve team in 2022 and look forward to bringing Bhang’s amazing cannabis-infused products to Trulieve customers throughout the US.”

About Bhang

Bhang is committed to making the fairly enjoyable ridiculously fun. For over a decade Bhang has delivered exceptional sensory experiences to consumers through its extensive portfolio of over 50 master-chef-created cannabis, CBD and terpene products including gourmet chocolates, pre-rolls, CBD isolate, and Hempsticks. Bhang’s highly-awarded chocolates are among the top-selling edibles in 7 U.S. states and Canada. Bhang’s CBD products are globally distributed and are known for being safe, efficacious and delicious. Learn more at www.bhangnation.com and purchase our high-quality CBD products at www.bhangcbd.com.

About Trulieve

Trulieve is an industry-leading, vertically integrated cannabis company and multi-state operator in the U.S. operating in 11 states, with leading market positions in Arizona, Florida, and Pennsylvania. Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to cannabis, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF.

To learn more about Trulieve, visit Trulieve.com.

FORWARD-LOOKING STATEMENTS

This press release contains statements which constitute “forward‐looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of the Company with respect to future business activities. Forward‐looking information is often identified by the words “may,” “would,” “could,” “should,” “will,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “expect” or similar expressions and include information regarding: (i) statements regarding the future direction of the Company; (ii) the ability of the Company to successfully achieve its business and financial objectives; (iii) plans for expansion of the Company into new jurisdictions; and (iv) expectations for other economic, business, and/or competitive factors. Investors are cautioned that forward‐looking information is not based on historical facts but instead reflect the Company’s management’s expectations, estimates or projections concerning the business of the Company’s future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward‐looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements. Among the key factors that could cause actual results to differ materially from those projected in the forward‐looking information are the following: changes in general economic, business and political conditions, including changes in the financial markets; in particular, in the ability of the Company to raise debt and equity capital in the amounts and at the costs that it expects; adverse changes in the public perception of cannabis; decreases in the prevailing prices for cannabis and hemp products in the markets that the Company operates in; adverse changes in applicable laws or adverse changes in the application or enforcement of current laws; the cannabis market is highly regulated and those regulations and enforcement priorities of governmental authorities may change; compliance with extensive government regulation and related costs; and other risks described in the Company’s Listing Statement, dated July 9, 2019, and other filings on www.sedar.com. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward‐looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward‐looking information except as otherwise required by applicable law.

Neither CSE nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release. ‎

Investors contact:
J. Graham Simmonds
Executive Chairman of the Board
Bhang Inc.
(416) 843-2881
[email protected]

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

The announcement celebrates GABY’s commitment to honoring the traditional cannabis culture while building a sustainable, scalable operation

SAN DIEGO, CA / ACCESSWIRE / October 19, 2021 / GABY Inc. (“GABY” or the “Company”) (CSE:GABY)(OTCQB:GABLF), a California consolidator of cannabis dispensaries and the parent company of San Diego’s Mankind Dispensary (“Mankind”), announces a series of initiatives that have helped steer Mankind towards operational and cultural improvements since acquiring the dispensary in April 2021.

Highlights of these operational improvements include:

• The onboarding of several key positions including – Simon Lileikis as President (Starbucks), Marshall Minor as CFO (Shryne Group/STIIIZY), and Rick Foltz as Director of Retail Ops (Art of Shaving, Nike).
• Implemented $2.3 MM in annual savings commencing in Q4 -21 through payroll savings and operating cost efficiencies.
• Logistics improvements at its distribution operation, Wild West Industries, Inc. (“Wild West Industries”), improving inventory turns, and reducing inventory on hand down from 45 days to 20 days.
• Launched its proprietary brands onto Mankind shelves accounting for roughly 20% of cannabis flower sales at Mankind. GABY’s newest brand, Kind Republic sold over $1MM in Mankind dispensary in just over 6 months and boasts avariable gross margin of almost 75%.
• Restructured delivery business with expected revenue increase over the next 12 months of $1MM, by extending delivery hours, expanding the fleet and reach of the business to meet existing demand.
• Established foundation for consolidation by creating an operations manual by which acquired dispensaries will operate – similar to a franchise model.
• Strategically remerchandised for greater influence over consumer buying decisions giving priority to higher margin and proprietary products and facilitating expansion of basket size. Every $1 increase in average basket size adds $300,000 in additional annual revenue.
• Using marketing analytics to target consumers with more effective messages and promotional programs of particular interest to them.

These operational improvements come as GABY places a strong emphasis on company culture and community impact, proving that these operational improvements can be executed while simultaneously making Mankind a more employee and community focused institution.

“Cannabis is an industry unlike any other – few other industries touch on medicinal, recreational, cultural, and social verticals simultaneously,” said Margot Micallef, Founder, and CEO of GABY Inc. “Success in cannabis hinges on understanding the uniqueness of the dispensary ecosystem, and how to best balance operational efficiency with cultural, employee, and consumer needs. I’m pleased to say, GABY is doing that.”

Cannabis Idea Share Event. Pictured, L-R: Purchasing Manager Zac Larson, Lead Assistant Store Manager Sam Golden, Cannabis Consultant Sam Mendillo, VP of Marketing and Communication John Butters, Cannabis Consultant Tyra Mayeselder, Founder and CEO Margot Micallef. Photo Credit: Charlie Rohlfs

The cultural and community based initiatives executed at Mankind include:

• Empowering employees as owners by offering Restricted Stock Units in all employee compensation packages enabling all full-time employees of the Company to become owners.
• The launching of Mankind’s “Plant. People. Planet.” initiative, which inspires mutual action between employees and customers through fundraising and community involvement efforts. Current charity partners include The Last Prisoner Project, Cannabis for Conservation, and The Brahman Project.
• The launching of Mankind’s “Tree Planting Initiative” – which plants a tree together with the Eden Project, for every purchase made at Mankind.
• The development of internal education and idea sharing initiatives, bringing executives, managers, and entry level staff together to ensure channels for communication exist at all levels.

About GABY Inc.

GABY Inc. is a California-focused retail consolidator and the owner of Mankind Dispensary, one of the oldest licensed dispensaries in California. Mankind is a well-known, and highly respected dispensary with deep roots in the California cannabis community operating in San Diego, California. Mankind curates and sells a diverse portfolio of products, including its own proprietary brands, Lulu’s and Kind Republic. A pioneer in the industry with a strong management team with experience in retail, consolidation, and cannabis, GABY is poised to grow its retail operations both organically and through acquisition.

GABY’s shares trade on the Canadian Securities Exchange (“CSE”) under the symbol “GABY” and on the OTCQB under the symbol “GABLF”. For more information on GABY, visit GABYInc.com

Media Contact:
Senior Communications Manager
Charlie Rohlfs
(631)579-0858
[email protected]

General

Margot Micallef, Founder & CEO at [email protected] or Investor Relations at [email protected] or 800-674-2239

Disclaimer and Forward-Looking Information

The CSE does not accept responsibility for the adequacy or accuracy of this release. Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties, certain of which are beyond the control of the Company. Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. Forward-looking statements include, but are not limited to, the Company’s future operational and cultural improvements and the anticipated benefits of such operational and cultural improvements on the future business, operations or financial results of the Company, the Company’s business strategy, including its plans to expand organically and through future acquisitions, and the Company’s anticipated operational efficiencies. Although GABY believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because GABY can give no assurance that they will prove to be correct. By its nature, such forward-looking information is subject to various risks and uncertainties, which could cause the actual results and expectations to differ materially from the anticipated results or expectations expressed. Without limitation, these risks and uncertainties include: the severity of the COVID-19 pandemic; risks associated with the cannabis industry in general; failure to benefit from partnerships or successfully integrate acquisitions; actions and initiatives of federal, state and provincial governments and changes to government policies and the execution and impact of these actions, initiatives and policies; the size of the medical-use and adult-use cannabis market; competition from other industry participants; adverse United States (“U.S.”), Canadian and/or global economic conditions; failure to comply with certain regulations; and departure of key management personnel or inability to attract and retain talent. GABY undertakes no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.

To the extent any forward-looking information in this press release constitutes “future-oriented financial information” or “financial outlooks” within the meaning of applicable Canadian securities laws, such information is being provided to demonstrate the anticipated benefit of the implementation of the Company’s operational and cultural improvements and the reader is cautioned that this information may not be appropriate for any other purpose and the reader should not place undue reliance on such future-oriented financial information and financial outlooks. Future-oriented financial information and financial outlooks, as with forward-looking information generally, are, without limitation, based on the assumptions and subject to the risks set out above under the heading “Disclaimer and Forward-Looking Information”. The Company’s actual financial position and results of operations may differ materially from its management’s current expectations and, as a result, the Company’s actual revenue may differ materially from the prospective revenue projections provided in this press release. Such information is presented for illustrative purposes only and may not be an indication of the Company’s actual financial position or results of operations.

Each of Mankind and Wild West Industries, are subsidiaries of GABY and hold a cannabis license in the State of California. Readers are cautioned that unlike in Canada which has Federal 032320-F legislation uniformly governing the cultivation, distribution, sale and possession of medical cannabis under the Cannabis Act (Federal), in the U.S., cannabis is largely regulated at the State level. Cannabis is legal in the State of California; however, cannabis remains illegal under U.S. federal laws. Notwithstanding the permissive regulatory environment of cannabis at the State level, cannabis continues to be categorized as a controlled substance under the Controlled Substances Act in the U.S. and as such, cannabis-related practices or activities, including without limitation, the manufacture, importation, possession, use or distribution of cannabis are illegal under U.S. federal law. To the knowledge of the Company, the businesses operated by each of GABY’s subsidiaries are conducted in a manner consistent with the State law of California, as applicable, and are in compliance with regulatory and licensing requirements applicable in the State of California, respectively. However, readers should be aware that strict compliance with State laws with respect to cannabis will neither absolve GABY, or its subsidiary of liability under U.S. federal law, nor will it provide a defense to any federal proceeding in the U.S. which could be brought against any of GABY, or its subsidiary. Any such proceedings brought against GABY, or its subsidiary may materially adversely affect the Company’s operations and financial performance generally in the U.S. market specifically.

SOURCE: GABY Inc.

MIAMI, Sept. 16, 2021 /PRNewswire/ – Fluent by Cansortium Inc. (CSE: TIUM.U) (OTCQX: CNTMF) (“Fluent,” “Cansortium,” or the “Company”), a vertically-integrated cannabis company operating under the Fluent brand, today announced the opening of Fluent Fruitland Park, the Company’s 27^th retail location in Florida.

The new dispensary is located at 3460 US-27, Fruitland Park, FL 34731. This location is only 10 miles away from the largest retirement community in the United States—The Villages. This community also represented the country’s fastest growing metropolitan area over the past decade with more than 130,000 residents as of 2020. Fluent Fruitland Park will offer a broad assortment of cannabis products, including Fluent flower and pre-rolls, Sweetwater premium flower, Black Line potency oils, Moods oils and Fluent Gels by Smokiez, among other Fluent product lines.

“We are thrilled to begin offering premium-quality cannabis products to the medical marijuana patients in Fruitland Park, as well as its vast and rapidly-growing surrounding communities,” said CEO Robert Beasley. “Fluent is one of only a few dispensaries serving the area and we will have many high-quality products to offer from our recently expanded cultivation projects throughout the state. Looking ahead, we have identified four additional retail locations to be opened in the first half of 2022, which would bring our total Florida footprint to 31 stores.”

The Fluent brand continually strives to set the standard for premium quality, consistently formulated cannabis products. All Fluent products in the Company’s Florida dispensaries use high-quality cannabis that is cultivated, processed, and packaged in strict compliance with Florida regulations. For consumers, the sleek, modern dispensaries provide a warm, welcoming and professional environment, with private consultation rooms and knowledgeable staff who carefully guide patients in selecting the right products and carefully safeguard patient privacy.

For a complete list of Fluent dispensary locations, current promotions, rewards programs and hours of operation, or to explore the entire Fluent product line and place an online order for home delivery anywhere in Florida, please visit www.getfluent.com.

About Fluent by Cansortium Inc.
Fluent by Cansortium Inc. is a vertically-integrated cannabis company with licenses and operations in Florida, Pennsylvania, Michigan and Texas. Fluent is dedicated to being one of the highest quality cannabis companies for the communities it serves. This is driven by Fluent’s unrelenting commitment to operational excellence in cultivation, production, distribution and retail. The Company is headquartered in Miami, Florida.

Cansortium Inc.’s common shares trade on the CSE under the symbol “TIUM.U” and on the OTCQX Best Market under the symbol “CNTMF.” For more information about the Company, please visit www.getfluent.com.

Forward-Looking Information
Certain information in this news release may constitute forward-looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “targets”, “expects” or “does not expect”, “is expected”, “an opportunity exists”, “is positioned”, “estimates”, “intends”, “assumes”, “anticipates” or “does not anticipate” or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “occur” or “be achieved”. In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management’s expectations, estimates, and projections regarding future events.

Forward-looking information is necessarily based on many opinions, assumptions, and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions, and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in the public documents of the Company available at www.sedar.com. These factors are not intended to represent a complete list of the factors that could affect the Company; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

For further information: www.getfluent.com

Company Contact 
Robert Beasley, CEO
(305) 900-6266
www.getfluent.com

Investor Relations Contact
Sean Mansouri, CFA
Elevate IR
(949) 200-4603
[email protected]

Media Contact
Julie Dietel
Grasslands: A Journalism-Minded Agency 
[email protected]
(978) 502-7705

SOURCE Cansortium Inc

Related Links

http://www.getfluent.com/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

MIAMI, Aug. 20, 2021 /PRNewswire/ – Cansortium Inc. (CSE: TIUM.U) (OTCQX: CNTMF) (“Cansortium” or the “Company”), a vertically-integrated cannabis company operating under the Fluent brand, today announced the opening of Fluent Mechanicsburg, the Company’s 2^nd retail location in Pennsylvania and its 28^th dispensary overall.

The new dispensary is located at 6200 Carlisle Pike, Mechanicsburg, PA 17050. This 4,000+ ft² location is in a small shopping center with ample parking, right off one of the principal commercial roads in the Harrisburg–Carlisle metropolitan area. Fluent Mechanicsburg will offer patients a broad assortment of cannabis products, including whole flower, oil cartridges, tinctures and concentrates.

“We are thrilled to open our second dispensary in Pennsylvania and begin serving the great community of Mechanicsburg and Cumberland County,” said CEO Robert Beasley. “Pennsylvania is one of the largest medical cannabis markets in the country—on pace to do more than $1 billion of annual sales in 2021—and we are in the early innings of capitalizing on strong growth in the state. Our medical dispensary permit allows for three different retail locations, and we remain on track to open our third store later this year.”

The Fluent brand continually strives to set the standard for premium quality, consistently formulated cannabis products. All Fluent products in the Company’s Florida dispensaries use high-quality cannabis that is cultivated, processed, and packaged in strict compliance with Florida regulations. For consumers, the sleek, modern dispensaries provide a warm, welcoming and professional environment, with private consultation rooms and knowledgeable staff who carefully guide patients in selecting the right products and carefully safeguard patient privacy.

For a complete list of Fluent dispensary locations, current promotions, rewards programs and hours of operation, or to explore the entire Fluent product line and place an online order for home delivery anywhere in Florida, please visit www.getfluent.com.

About Cansortium Inc.
Cansortium is a vertically-integrated cannabis company with licenses and operations in Florida, Pennsylvania, Michigan and Texas. The Company operates under the Fluent brand and is dedicated to being one of the highest quality cannabis companies for the communities it serves. This is driven by Cansortium’s unrelenting commitment to operational excellence in cultivation, production, distribution and retail. The Company is headquartered in Miami, Florida.

Cansortium Inc.’s common shares trade on the CSE under the symbol “TIUM.U” and on the OTCQX Best Market under the symbol “CNTMF.” For more information about the Company, please visit www.getfluent.com.

Forward-Looking Information
Certain information in this news release may constitute forward-looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “targets”, “expects” or “does not expect”, “is expected”, “an opportunity exists”, “is positioned”, “estimates”, “intends”, “assumes”, “anticipates” or “does not anticipate” or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “occur” or “be achieved”. In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management’s expectations, estimates, and projections regarding future events.

Forward-looking information is necessarily based on many opinions, assumptions, and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions, and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in the public documents of the Company available at www.sedar.com. These factors are not intended to represent a complete list of the factors that could affect the Company; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

For further information: www.getfluent.com

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

SAN DIEGO, CA / ACCESSWIRE / July 27, 2021 / GABY Inc. (“GABY” or the “Company“) (CSE:GABY)(OTCQB:GABLF), a California consolidator of cannabis dispensaries and the parent company of San Diego’s Mankind Dispensary (“Mankind“), is pleased to announce the addition of Marshall Minor as Chief Financial Officer (CFO) of GABY.

Mr. Minor brings an extensive resume to GABY’s executive team. Most recently, Marshall was CFO of Shryne Group – a multi-state operator in the cannabis industry with operations in California, Michigan, Washington and Nevada, with a combined 10 operating dispensaries and revenues in excess of $100 million. Prior to Shryne Group, Mr. Minor was the CFO of Solace Holdings/Aether Gardens, a private equity backed cannabis company focused on production and extraction. Further to Marshall’s strong cannabis knowledge, he brings senior executive experience as a CFO of a billion-dollar real estate development company, Vice President of Corporate Finance and M&A for MGM Resorts in Las Vegas and extensive capital markets and investment banking experience with bulge bracket firms in New York and regional firms in California.

“My diverse career path has allowed me to work across several high-caliber companies, generating development growth in some of the most sophisticated and competitive markets within cannabis, real estate, and investment banking,” said Minor. “I’m looking forward to applying my experience gained on Wall Street, Main Street, and in the cannabis world to GABY and helping it establish its place as a leader in the cannabis market,” said Mr. Minor.

“Marshall’s hiring comes at an exciting time for GABY as it expands its retail operations across California,” said Margot Micallef, Founder and CEO of GABY. “Mr. Minor’s impressive executive history in cannabis, gaming and investment banking will be a major asset to GABY shareholders as we continue to make acquisitions and expand the GABY brand across California. The right leadership talent is paramount in a high growth company like GABY, and I am excited about GABY’s future with the executive team I have brought together.”

GABY continues to realize synergies from its merger with Mankind and will be consolidating its distribution and manufacturing facilities from a segmented multi-city effort into a single streamlined operation based out of its headquarters of San Diego. To facilitate this change, GABY will be closing its Sonoma Pacific Distribution location in Santa Rosa and will transition all pertinent operations to Wild West Industries. This move will allow Mankind to better serve its customers by decreasing time-to-shelf of products, improving availability of proprietary products, and ensuring a single point of quality assurance, all while furthering the Company’s commitment to sustainability through the decrease of transportation emissions.

The Company is also pleased to confirm that in keeping with its policy of ensuring that all full-time employees of GABY or its subsidiaries are aligned with GABY’s shareholders, it has issued an aggregate of 16,200,000 Restricted Share Units (each an “RSU“) to 102 employees pursuant to the terms of its Restricted Share Unit Plan. Further, the Company has issued an aggregate of 940,000 common shares in the capital of the Company (“Common Shares“) to employees with vested RSU’s and 1,465,667 Common Shares to three consultants who elected pursuant to their consulting agreements to receive compensation in Common Shares instead of cash.

About GABY Inc.
GABY Inc. is a California-focused retail consolidator and the owner of Mankind Dispensary, one of the oldest licensed dispensaries in California. Mankind is a well-known, and highly respected dispensary with deep roots in the California cannabis community operating in San Diego, California. GABY curates and sells a diverse portfolio of products, including its own proprietary brands, Kind Republic and Lulu’s through Mankind and manufactures and distributes the brands through its wholly-owned subsidiary, Wild West Industries, based in San Diego. A pioneer in the industry with a multi-vertical retail foundation, and a strong management team with experience in retail, consolidation, and cannabis, GABY is poised to grow its retail operations both organically and through acquisition.

GABY’s shares trade on the Canadian Securities Exchange (“CSE“) under the symbol “GABY” and on the OTC under the symbol “GABLF”. For more information on GABY, visit www.GABYInc.com

For further inquiries, please contact:
General
Margot Micallef, Founder & CEO or Investor Relations at [email protected] or 800-674-2239.

Media Contact:
Charlie Rohlfs
Senior Communications Manager
GABY Inc.
[email protected]

Disclaimer and Forward-Looking Information
The CSE does not accept responsibility for the adequacy or accuracy of this release. Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties, certain of which are beyond the control of the Company. Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. Forward-looking statements include, but are not limited to, the Company’s realization of synergies from its merger with Mankind, the expansion of the Company’s retail operations in California, future acquisitions of the Company, and the closing of the Company’s Sonoma Pacific Distribution location in Santa Rosa and the transition of the Company’s operations to Wild West Industries. Although GABY believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because GABY can give no assurance that they will prove to be correct. By its nature, such forward-looking information is subject to various risks and uncertainties, which could cause the actual results and expectations to differ materially from the anticipated results or expectations expressed. Without limitation, these risks and uncertainties include: the severity of the COVID-19 pandemic; risks associated with the cannabis industry in general; failure to benefit from partnerships or successfully integrate acquisitions; actions and initiatives of federal, state and provincial governments and changes to government policies and the execution and impact of these actions, initiatives and policies; the size of the medical-use and adult-use cannabis market; competition from other industry participants; adverse U.S., Canadian and global economic conditions; failure to comply with certain regulations; and departure of key management personnel or inability to attract and retain talent. GABY undertakes no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.

Each of Mankind and Sonoma Pacific Distribution, Inc., are subsidiaries of GABY and hold a cannabis license in the State of California. Readers are cautioned that unlike in Canada which has Federal 032320-F legislation uniformly governing the cultivation, distribution, sale and possession of medical cannabis under the Cannabis Act (Federal), in the United States (“U.S.“), cannabis is largely regulated at the State level. Cannabis is legal in the State of California; however, cannabis remains illegal under U.S. federal laws. Notwithstanding the permissive regulatory environment of cannabis at the State level, cannabis continues to be categorized as a controlled substance under the Controlled Substances Act in the U.S. and as such, cannabis-related practices or activities, including without limitation, the manufacture, importation, possession, use or distribution of cannabis are illegal under U.S. federal law. To the knowledge of the Company, the businesses operated by each of GABY’s subsidiaries are conducted in a manner consistent with the State law of California, as applicable, and are in compliance with regulatory and licensing requirements applicable in the State of California, respectively. However, readers should be aware that strict compliance with State laws with respect to cannabis will neither absolve GABY, or its subsidiary of liability under U.S. federal law, nor will it provide a defense to any federal proceeding in the U.S. which could be brought against any of GABY, or its subsidiary. Any such proceedings brought against GABY, or its subsidiary may materially adversely affect the Company’s operations and financial performance generally in the U.S. market specifically.

Neither the CSE nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

SOURCE: GABY Inc.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Captor Retail Group’s Eighth Dispensary in California to Serve Customers Throughout Santa Barbara County

TORONTO, May 27, 2021 (GLOBE NEWSWIRE) — Captor Capital Corp. (CSE: CPTR; FRANKFURT: NMVA; STUTTGART: NMVA), (“Captor” or the “Company”), is pleased to announce it will open a brand-new retail cannabis dispensary location in Goleta, California, this month.

The Santa Barbara County retail dispensary, Captor Retail Group’s eighth dispensary in California, will open Friday, May 28, 2021. The new retail dispensary will be located at 290 Storke Road, Goleta, California 93117, in a high-traffic shopping plaza with Target, Costco, and Home Depot locations nearby. The dispensary will offer qualified customers in-store, delivery, and order-ahead pickup options.

“We’re thrilled to join the Goleta community and to bring our premium cannabis flower and unique retail experience to Santa Barbara County,” said Adam Wilks, CEO of Captor Retail Group. “This new location will allow us to better serve our customers throughout Southern California as we continue to execute on our aggressive retail growth strategy.”

“I’d like to congratulate the entire CRG team for working tirelessly to open up our Goleta location before the holiday weekend,” said John Zorbas, CEO of Captor Capital. “We look forward to building a long and productive relationship with the Goleta community, and we cannot wait to welcome our first customers this weekend.”

The Goleta location joins the existing Captor Retail Group portfolio, which includes CHAI Cannabis Co.-branded dispensaries in Santa Cruz and Castroville, and One Plant California-branded dispensaries in Salinas, Antioch, Atwater, El Sobrante, and Lompoc.

Captor Capital intends to open its ninth dispensary in California, in Palm Springs, by the early third quarter of this year, subject to the receipt of all necessary municipal and regulatory approvals. Customers can learn more about CHAI Cannabis Co. and One Plant California locations by visiting https://captorcapital.com/retailstores/.

Contact Information

Captor Capital Corp.
Gavin Davidson, Communications
Email: [email protected]

For media inquiries, please contact:
Daniel Nussbaum
AMW PR
Phone: 917.232.8960
Email: [email protected]

About Captor Capital Corp.

Captor Capital Corp. is a Canadian vertically integrated cannabis company listed on the Canadian Securities Exchange, and the Frankfurt and Stuttgart stock exchanges. Captor provides recreational marijuana products to consumers, as well as other high demand cannabis-based goods. The Company follows a strategy of acquiring cash flowing established companies and organizations with growth potential that require capital to scale.

Cautionary Statements

This press release contains or refers to forward-looking information and is based on current expectations that involve a number of business risks and uncertainties. Factors that could cause actual results to differ materially from any forward-looking statement include, but are not limited to availability of investment opportunities, economic circumstances, market fluctuations and uncertainties, uncertainties relating to the availability and costs of financing needed in the future, changes in equity markets, inflation, changes in exchange rates, and the other risks involved in the investment industry and junior capital markets. Forward-looking statements are subject to significant risks and uncertainties, and other factors that could cause actual results to differ materially from expected results. Readers should not place undue reliance on forward-looking statements. These forward-looking statements are made as of the date hereof and the Company assumes no responsibility to update them or revise them to reflect new events or circumstances other than as required by law.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.